U.S. pharma giant copyright scrapped two experimental weight loss products previous calendar year—a after-each day capsule, lotiglipron, as a result of elevated liver enzymes along with a twice-day-to-day tablet, danuglipron, on account of strong side effects—but CEO Albert Bourla has stated the company is determined to “Perform and earn” w